Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5274 ARTÍCULOS , VIENDO DEL 1186 AL 1200

Cellular and Molecular Events Leading to Paraquat-Induced Apoptosis: Mechanistic Insights into Parkinson's Disease Pathophysiology

See WZC, Naidu R, Tang KS.

Mol Neurobiol. 2022 Jun;59(6):3353-3369. doi: 10.1007/s12035-022-02799-2. Epub 2022 Mar 19.

A Review on the Arylpiperazine Derivatives as Potential Therapeutics for the Treatment of Various Neurological Disorders

Kumar B, Kumar N, Thakur A, Kumar V, Kumar R, Kumar V.

Curr Drug Targets. 2022;23(7):729-751. doi: 10.2174/1389450123666220117104038.

The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England

Chaudhuri KR, Pickard AS, Alobaidi A, Jalundhwala YJ, Kandukuri PL, Bao Y, Sus J, Jones G, Ridley C, Oddsdottir J, Najle-Rahim S, Madin-Warburton M, Xu W, Schrag A.

Pharmacoeconomics. 2022 May;40(5):559-574. doi: 10.1007/s40273-022-01132-y. Epub 2022 Mar 21.

Evidence That Substantia Nigra Pars Compacta Dopaminergic Neurons Are Selectively Vulnerable to Oxidative Stress Because They Are Highly Metabolically Active

Ni A, Ernst C.

Front Cell Neurosci. 2022 Mar 4;16:826193. doi: 10.3389/fncel.2022.826193. eCollection 2022.

Thymoquinone in Ocular Neurodegeneration: Modulation of Pathological Mechanisms via Multiple Pathways

Mahmud NM, Paraoan L, Khaliddin N, Kamalden TA.

Front Cell Neurosci. 2022 Mar 2;16:786926. doi: 10.3389/fncel.2022.786926. eCollection 2022.

Salivary alpha-synuclein as a potential fluid biomarker in Parkinson's disease: A systematic review and meta-analysis

Kharel S, Ojha R, Bist A, Joshi SP, Rauniyar R, Yadav JK.

Aging Med (Milton). 2022 Jan 24;5(1):53-62. doi: 10.1002/agm2.12192. eCollection 2022 Mar.

Editorial: Non-invasive Brain Stimulation for Neurodegenerative Disorders: From Investigation to Therapeutic Application

Di Lorenzo F, Oliviero A, Guerra A, Fried PJ.

Front Neurol. 2022 Mar 3;13:820942. doi: 10.3389/fneur.2022.820942. eCollection 2022.

The Effects of Non-Invasive Brain Stimulation on Quantitative EEG in Patients With Parkinson's Disease: A Systematic Scoping Review

Costa TDC, Godeiro Júnior C, Silva RAE, Dos Santos SF, Machado DGDS, Andrade SM.

Front Neurol. 2022 Mar 2;13:758452. doi: 10.3389/fneur.2022.758452. eCollection 2022.

Manganese-induced parkinsonism responsive to intranasal insulin: A case report

Salari M, Etemadifar M, Dargahi L, Valian N, Rezaee M.

Clin Case Rep. 2022 Mar 13;10(3):e05562. doi: 10.1002/ccr3.5562. eCollection 2022 Mar.

Editorial: Dopamine Neuron Diversity in Circuits and Diseases

Poulin JF, Lerner TN, Howe MW.

Front Neural Circuits. 2022 Mar 2;16:856716. doi: 10.3389/fncir.2022.856716. eCollection 2022.

Therapeutic targeting of mitophagy in Parkinson's disease

Masaldan S, Callegari S, Dewson G.

Biochem Soc Trans. 2022 Apr 29;50(2):783-797. doi: 10.1042/BST20211107.

Nuclear imaging in Parkinson's disease: The past, the present, and the future

Golan H, Volkov O, Shalom E.

J Neurol Sci. 2022 May 15;436:120220. doi: 10.1016/j.jns.2022.120220. Epub 2022 Mar 9.

Embedding digital chronotherapy into bioelectronic medicines

Fleming JE, Kremen V, Gilron R, Gregg NM, Zamora M, Dijk DJ, Starr PA, Worrell GA, Little S, Denison TJ.

iScience. 2022 Mar 4;25(4):104028. doi: 10.1016/j.isci.2022.104028. eCollection 2022 Apr 15.

Propagation of tau and α-synuclein in the brain: therapeutic potential of the glymphatic system

Lopes DM, Llewellyn SK, Harrison IF.

Transl Neurodegener. 2022 Mar 21;11(1):19. doi: 10.1186/s40035-022-00293-2.

Inflammation in dementia with Lewy bodies

Amin J, Erskine D, Donaghy PC, Surendranathan A, Swann P, Kunicki AP, Boche D, Holmes C, McKeith IG, O'Brien JT, Teeling JL, Thomas AJ.

Neurobiol Dis. 2022 Jun 15;168:105698. doi: 10.1016/j.nbd.2022.105698. Epub 2022 Mar 18.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias